We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Fluidigm, OpGen Collaborate
News

Fluidigm, OpGen Collaborate

Fluidigm, OpGen Collaborate
News

Fluidigm, OpGen Collaborate

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Fluidigm, OpGen Collaborate "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Under the terms of the five-year agreement, the firms will develop tests for the identification, screening, and surveillance of multi-drug resistant pathogens built on Fluidigm's Juno instrument for automating SNP genotyping assays and its Biomark real-time endpoint PCR. The firms will cooperate on quality and regulatory compliance and will have the option to extend the agreement for an additional five years.

"With this expanded relationship, OpGen anticipates developing customized solutions for our CLIA lab customers, strategic partners, and testing laboratories globally," OpGen President Kevin Krenitsky said in a statement, noting that the firm's Acuitas MDRO Gene Test and Resistome Test use Fluidigm's microfluidics.

Steve McPhail, Fluidigm's general manager for production genomics, said, that the partners will seek government funding to develop new products, including molecular information analytics, based on each other's technologies.

Gaithersburg, Maryland-based OpGen offers molecular testing and informatics to help healthcare organizations fight drug-resistant pathogens. 


Advertisement